Drugs / Study Part 1: KRP203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01830010 | Jun 2013 → Aug 2018 | hematopoietic and lymphoid cell neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Study Part 1: KRP203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01830010 ↗ |
| Action | Inhibit | “blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs” PMID 36343893 ↗ Nov 2022 |